We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Drug Targets – Products

Drug Kinetics SPR

Optimize Your Affinity and Kinetics Data Analysis

Accurate kinetics and affinity data is essential for predicting the efficacy of novel therapeutics and for making quick decisions about weak candidates. However, analysis methods that require labelling can cause steric interference and influence data outcomes.
Sygnature Discovery logo.
Product News

Sygnature Discovery Launches Its LPS In Vivo Model To Profile Early-Stage Anti-Inflammatory Drugs

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.
Assess Small Molecule Kinetics and Affinity in Just One Step - image
App Note / Case Study

Assess Small Molecule Kinetics and Affinity in Just One Step

This application note demonstrates how reliable kinetics and affinity can be obtained from single measurement data, increasing sample throughput and saving sample material.
Scientists working with assays

Achieve Successful BLI and SPR Assays

Designing and performing assays that accurately measure the binding kinetics of biomolecular interactions requires highly technical skills. Hence, such methods can feel out of reach for many scientists.
Successful BLI

Good Data. Rich Insights. More Discoveries.

Label-free biosensor technologies have emerged as a promising approach to identify high-value hits with a strong likelihood of success as a therapeutic. Unlike traditional approaches of drug discovery, they are fast, sensitive, and come with improved success rates towards high-value drug candidates.
Successful SPR Assays
App Note / Case Study

Determining Real-Time Kinetics and Affinity

This compendium serves as a user-friendly reference for assay design on both bio-layer interferometry (BLI) and surface plasmon resonance (SPR) systems.
The Orbit Discovery logo
Product News

Orbit Discovery and Evergreen Discovery Collaborate To Discover Peptides for Targeting Radiopharmaceuticals

Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.
The Cardiff Oncology logo.
Product News

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase II Randomized Trial

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.
The Carterra logo
Product News

Carterra Launches the LSAXT High-Throughput SPR Biosensor at SLAS2023

Carterra Inc. launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA.
New chief science officer, Dr. Lisa Jones
Product News

GenNext Technologies Appoints Dr. Lisa Jones of UCSD to the Role of Chief Science Officer

GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.